Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) has appointed Sung Lee to serve as executive vice president and chief financial officer. Lee joins Brisbane, CA-based Sangamo after 14 years at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was most recently a senior vice president leading financial planning and analysis, and investor relations. Sangamo and partner Pfizer (NYSE: [[ticker:PFE]]) are developing a gene therapy, SB-525, for hemophilia.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
